BioCardia’s CardiAMP Therapy Cuts LVEDV by >20ml/m2 in HFrEF Patients
BioCardia’s Phase III CardiAMP HF trial echocardiography shows treated patients with elevated NTproBNP experienced over 20ml/m2 reduction in left ventricular end diastolic volume (p=0.02) and 15ml/m2 reduction in end systolic volume (p=0.01). These results align with primary endpoints of fewer major adverse cardiovascular events and improved quality of life.
1. Echocardiography Outcomes Indicate Remodeling Benefits
Blinded core-lab measurements demonstrate that CardiAMP-treated patients showed reduced pathological left ventricular remodeling, with LVEDV and LVESV decreasing by clinically meaningful margins compared with controls.
2. Significant Reductions in Biomarker-Defined Subgroup
In patients with elevated NTproBNP, LVEDV dropped by over 20ml/m2 (p=0.02) and LVESV by 15ml/m2 (p=0.01), marking statistically significant improvements in the prespecified subgroup.
3. Alignment with Clinical Endpoints and Future Plans
These echo findings correspond to the trial’s primary and key secondary endpoints of lowered major adverse cardiovascular events and enhanced quality of life, supporting continued CardiAMP development and potential regulatory discussions.